Last updated on August 2019

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)


Brief description of study

The purpose of this study is to evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events (AEs). The primary hypotheses are that 1) V114 is noninferior to Prevnar 13 as measured by the serotype specific OPA GMTs for 13 shared serotypes at 30 days postvaccination and that 2) V114 is superior to Prevnar 13 as measured by serotype-specific OPA GMTs for 2 unique serotypes in V114 at 30 days postvaccination.

Clinical Study Identifier: NCT03950622

Find a site near you

Start Over